Loading…
Loading…
BAL (iPath Series B Bloomberg Cotton Subindex Total Return ETN) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
BAL does not currently pay a dividend.
See exactly how BAL's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for BAL and 80,000+ other tickers.
This Exchange Traded Note (ETN) provides investors with exposure to commodity markets by tracking futures contracts, rather than offering direct ownership of the physical goods themselves. The benchmark index that this ETN aims to replicate is composed of one or more futures agreements on the designated commodity. Its objective is to mirror the potential returns generated from two sources: firstly, a straightforward, unleveraged investment in those specific futures contracts, and secondly, the interest income that could be accrued from cash collateral placed in particular Treasury Bills.
[url="]Agenus[/url] Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that three-year survival data from the Phase 1b C-800-01 study
Funding is awarded following successful completion of IND-enabling studies and clinical study authorization USD 6 million in additional funding to support antibiotic BAL2420 (LptA inhibitor) first-in-human clinical study Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, April 09, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that it was awarded an additional USD 6 million from CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator), a global non-profit partnership dedicated to supporting the early development of antibacterial products.
Allschwil, Switzerland, March 23, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today the dosing of the first healthy volunteer in the first-in-human phase 1 study of BAL2420, evaluating the safety, tolerability and pharmacokinetics of this lipopolysaccharide transport protein A (LptA) inhibitor. BAL2420 belongs to a novel class of antibiotics.
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, September 16, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services, committed the next USD 25 million to Basilea to continue to advance the development of Basilea's novel antifungals fosmanogepix and BAL2062.
Addition of AgenT-797 with Checkpoint Inhibitors, BOT/BAL, and Chemotherapy Demonstrates Robust Immune Activation, Offering Potential to Overcome Refractory Gastric Cancers Addition of AgenT-797 with Checkpoint Inhibitors, BOT/BAL, and Chemotherapy Demonstrates Robust Immune Activation, Offering Potential to Overcome Refractory Gastric Cancers